Skip to main content
. Author manuscript; available in PMC: 2020 Jan 24.
Published in final edited form as: Neuropharmacology. 2017 Jun 3;123:126–135. doi: 10.1016/j.neuropharm.2017.06.002

Fig. 5. Repeated flupirtine administration reduces overall seizure burden and modifies disease progression during the acute phase of hypoxic-ischemic injury.

Fig. 5.

Flupirtine treatment initiated during the immediate reperfusion period and then continued for 3 more days (a daily dose of 25 mg/kg flupirtine), significantly reduced (A) the total number and (B) duration of electroclinical seizures over a 72 h period following hypoxia-ischemia (HI)-induction. Further, multiple flupirtine doses altered the evolution of disease and reduced (C) number and (D) duration of electroclinical seizures during the acute phase of hypoxic-ischemic injury. Data shown are mean ± SD. *p < 0.05, Student’s two-tailed t-test. ECS = electroclinical seizure, V = vehicle, F = flupirtine.